Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
As a comparison the overall renal survival over 12 trials has been reported to be 26% with current Standard of Care (SoC)1. This positive outcome served as Proof of Concept (PoC) for the potential of imlifidase to treat IgG-mediated serious autoimmune diseases.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
Gesynta Pharma’s first-in-class drug candidate GS-248 provides a combination of anti-inflammatory and vasodilatory effects by potently and selectively inhibiting microsomal prostaglandin E synthase-1 (mPGES-1).
Lead Product(s): GS-248
Therapeutic Area: Immunology Product Name: GS-248
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
The study is a multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial in patients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and immunogenicity of ABY-035.
Lead Product(s): ABY-035
Therapeutic Area: Immunology Product Name: ABY-035
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The data analysis conducted on the first 26 patients who has completed treatment indicates that AP1189 is safe and well tolerated at the current dose schedule.
Lead Product(s): AP1189
Therapeutic Area: Immunology Product Name: AP1189
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Positive data demonstrates potential to increase renal survival in anti-GBM antibody disease and marks an important milestone for expansion of imlifidase outside transplantation.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
New patent applications have been filed to extend exclusivity on Rabeximod, potentially to 2043. A patent application related to Covid-19 has also been filed.
Lead Product(s): Rabeximod
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
CHMP of the EMA has adopted a positive opinion, recommending conditional approval of IdefirixTM for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
Details:
Kancera plans a Phase II trial of its fractalkine receptor inhibitor KAND567 to prevent hyperinflammation in COVID-19 patients before they develop acute respiratory distress syndrome.
Lead Product(s): KAND567
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
The parties will develop and commercialize ABY-035 for multiple auto-immune diseases. Inmagene will Commercialize ABY-035 in mainland China, Hong Kong, Taiwan, and Macau, and South Korea, and will run developmental activities in the Asia Pacific region.
Lead Product(s): ABY-035
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Inmagene Biopharmaceuticals
Deal Size: $225.5 million Upfront Cash: $10.0 million
Deal Type: Partnership May 15, 2020
Details:
This proactive and strategic decision follows the initiation of preparatory work for substance capsulation that started early this year and is part of the Phase IIb program.
Lead Product(s): Rabeximod
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
